Follistatin 344 is a recombinant form of a natural muscle-regulating protein. It has strong preclinical results but is not an approved human therapy.

What is follistatin 344?

Follistatin is a natural glycoprotein in the body that binds and neutralizes myostatin and activin, two signals that limit muscle growth. “Follistatin 344” (FST-344) is the 344-amino-acid form, the predominant circulating isoform of the follistatin family.

Online, the name usually refers to a recombinant protein made in cell culture, or to a gene construct designed to express human FST-344. Researchers also study a shorter isoform, follistatin 315.

Both isoforms come from the FST gene and differ mainly in the length of the protein’s tail. Because the two behave differently in circulation and in tissue, results from one should not be assumed to apply to the other.

The mechanism is straightforward. Follistatin acts as a binding antagonist: it captures myostatin and related TGF-beta superfamily ligands before they reach their cell-surface receptors, which suppresses downstream SMAD2/3 signaling. In muscle, that signaling normally restrains protein synthesis and growth, so with less of it the brake eases. Reported binding to myostatin is in the high picomolar range, meaning follistatin holds on very tightly.

Why researchers care

Blocking two growth-limiting signals at once produces a larger effect than blocking myostatin alone. A 2007 PLoS ONE study (Lee) found that mice with follistatin expressed in muscle on a myostatin-null background had about four times the muscle mass of normal mice. Myostatin knockout alone gave roughly two- to three-fold gains.

That result is why follistatin-based approaches attract more interest than selective myostatin inhibitors. Follistatin is also studied in reproductive biology, where it binds activin in pituitary tissue and reduces FSH secretion.

Interest in this pathway began in the late 1990s, when researchers reported that mice lacking the myostatin gene had markedly larger muscles. Naturally occurring myostatin mutations have since been described in heavily muscled cattle breeds and in a rare human case. Those observations raised an obvious question: could the pathway be targeted to treat muscle loss? Follistatin, as an endogenous inhibitor, became a natural candidate.

The clinical motivation is conditions in which muscle wastes away, including muscular dystrophy, age-related sarcopenia and cachexia. Follistatin is not the only way to reach the pathway. Anti-myostatin antibodies and soluble ActRIIB decoys target the same biology by different routes, and they are the approaches most often compared with follistatin.

What the evidence does and doesn’t show

The strongest results come from animals and gene-therapy studies, not from the injectable peptide sold online. Claims about muscle gain, fat loss and recovery have not been shown safe or effective in humans.

• Follistatin 344 can increase muscle size in animal models.
• Human data come only from small gene-therapy trials in disease populations.
• There is no robust peer-reviewed evidence for general fitness, bodybuilding or anti-aging use in healthy people.
• Direct clinical trial data for injectable follistatin 344 is limited.

The human work most often cited involves delivering the follistatin 344 gene with a viral vector, not injecting the protein. Small early-phase studies in people with Becker muscular dystrophy are the best-known example. They were designed mainly to assess safety, enrolled very few participants, and cannot be extrapolated to healthy adults.

Animal results also transfer poorly for a structural reason. Gene therapy produces sustained expression inside the muscle itself, while an injected protein circulates and is cleared, so the exposure is fundamentally different. Extreme findings in mice, such as the four-fold gain above, are rarely matched in people. Other myostatin-targeting drugs tested in humans have generally shown smaller functional benefits than the animal data suggested.

Regulatory status

As of April 2026, no injectable follistatin product is FDA-approved for any indication.

• Products sold by research-chemical vendors are not regulated by the FDA, have not been evaluated for purity or safety in humans, and have no established injectable pharmacokinetics in humans.
• Follistatin 344 is not approved as a drug or supplement by the FDA, EMA or other major health authorities.
• In competitive sport, myostatin-binding proteins, including follistatin, are prohibited at all times under the WADA list.

Sources disagree on one point. Some sellers state that compounded follistatin 344 is available from licensed 503A pharmacies under a physician’s prescription. Other sources describe the injectable peptide as a research chemical with no recognized compounding status. Both cannot be right in the same sense, so a reader should verify any such claim with a pharmacist or the FDA’s published lists rather than a seller’s description.

A “research use only” label matters too. It means the seller is not representing the product as suitable for human use, and it shifts responsibility for how the product is used onto the buyer.

Risks to understand

Unregulated products carry practical risks that are separate from the science.

• Contamination and inconsistent purity.
• Dosing errors, since no validated human dose exists outside approved indications.
• Unknown effects on tissue growth.
• Effects beyond muscle: follistatin also acts on activin, which is involved in reproductive hormone signaling.
• Banned-substance violations for competitive athletes.

One guide advises that anyone outside formal research, without close medical oversight, should avoid follistatin 344. Because the long-term effects of altering growth-factor signaling are unknown, that caution applies with extra force to anyone who is pregnant or trying to conceive, has a hormone-sensitive condition, or has a history of cancer. These groups are not studied, so no one can say what the risk is.

How to read claims about follistatin 344

Most confusion comes from blurring what was studied with what is sold. Five checks help.

1. What was studied? Separate animal data from human data, and gene therapy from injected protein. A result in one does not carry over to the others.
2. How is the benefit worded? Phrases such as “studied for muscle preservation” can imply a proven benefit that the evidence does not support.
3. Is there an approval? Look for FDA or EMA approval. For follistatin, none exists for injectable products.
4. Is purity independently verified? A vendor’s own description is not verification. Ask for third-party lab testing of the specific batch.
5. Is a dose offered? No validated human dose exists outside approved indications, so any specific dose is an unsupported claim.

For anyone writing about this compound, the safest approach is to describe it as a research subject. State its regulatory status plainly, attribute findings to the species and study type they came from, and avoid promising results such as muscle gain, fat loss or faster recovery.

What would change the picture

The science may still evolve, and new trials could clarify follistatin’s role in human health. Three things would move the evidence from promising to usable:

• Randomized, controlled human trials of the specific product being sold, not of a related gene therapy.
• A defined dose, route and schedule, with long-term safety follow-up that includes hormonal and reproductive endpoints.
• Manufacturing standards that confirm identity and purity, which is what a formal approval pathway requires.

Until that work exists, claims that go beyond “studied in animals and in small gene-therapy trials” outrun the data. Readers and writers alike should hold that line.

Bottom line

Follistatin 344 is a well-characterized molecule with real preclinical findings, but those findings have not been translated into an approved or proven human therapy. Anyone considering it outside a registered clinical trial should talk to a physician first.